Christie Digital Christie Digital
Christie CounterAct UVC disinfection module
Overview Videos Specs Downloads

Christie® CounterAct products, with patented Care222® technology, emit filtered far-UVC 222nm light that has been shown in the lab to inactivate more than 99% of pathogens and disinfect surfaces—including SARS-CoV-2 (COVID-19), influenza, bacteria, and antibiotic-resistant superbugs.

Not all UVC light is created equal

We know ultraviolet (UV) light can effectively neutralize pathogens, but the typical 254nm wavelength can penetrate human eyes and skin, so it can only be used in unoccupied spaces where no people are present. CounterAct products contain Ushio’s patented Care222 lamps that emit far-UVC 222nm light, a sweet spot on the UV spectrum that’s not only effective against reducing pathogens but may be used around people. And Care222 is the only UVC technology with a proprietary optical filter that prevents longer UVC wavelengths from being emitted. Learn more about how far-UVC light technology works.

We thought of everything

  • Care222 is the world's first UVC technology with a proprietary optical filter that prevents the emission of longer UVC wavelengths that can harm humans
  • Programmable – Configurable to be effective against pathogens without exceeding the limits of existing exposure standards
  • As easy to install as traditional commercial lighting fixtures, with control via an app
  • Easy-to-service for straightforward lamp changes
  • Instant on/off at full output power, and frequent on/off cycles don’t affect lamp life
  • Able to operate over a wide range of ambient temperatures
  • RF-wireless
  • Available in both AC and DC power configurations
  • Fixtures are available in black or white to fit existing color schemes
  • Flexible leasing options are available

Top 3 reasons to choose Christie CounterAct

CounterAct may be used when people are present

CounterAct products with patented Care222 technology and proprietary filters emit far-UVC 222nm light that cannot penetrate healthy human skin when used in accordance with operational specifications

It’s effective

The patented far-UVC light that Care222 technology emits can reduce surface pathogens—including coronaviruses like the common cold and SARS-CoV-2, influenza, and bacteria

It’s an added layer of defense

CounterAct products with patented Care222 technology emit far-UVC 222nm light that damages the RNA of pathogens like coronaviruses provide an added layer of defense

Design services

We can work with you to determine how many CounterAct light modules fixtures you need to provide effective coverage of your indoor space. We offer consulting and installation services through our Professional Services group to help with a deployment strategy to add a layer of defense against pathogens in shared indoor spaces.

Christie CounterAct products with patented Care222 technology are not for use as or for medical devices or for use on humans or animals or to disinfect medical devices.

This product is not intended to diagnose, treat, cure, or prevent any disease.

The pathogen-reducing efficacy of Christie CounterAct products with patented Care222 technology and their use in occupied spaces is dependent on proper installation and operational specifications, in accordance with American Conference of Governmental Industrial Hygienists (ACGIH) guidelines.

Any references to “disinfection’ and “disinfecting” are referring generally to the reduction of pathogenic bioburden and are not intended to refer to any specific definition of the term as may be used for other purposes by the U.S. Food and Drug Administration or the U.S. Environmental Protection Agency.

The Care222® standard character mark and stylized logo mark are registered trademarks of Ushio America, Inc.’s patented technology, in the United States, European Union, and United Kingdom.


Let's return to the places we love - Christie CounterAct products with patented Care222 technology


Let's return to the places we love

Ushio Care222® Filtered Far UV-C Excimer


Ushio Care222 Far-UVC technology


Power supply

  • 24VDC ± 1.1V

Power consumption

  • 38W (DC version)

Rated current

  • 1600mA max


  • N/A

Emission wavelength

  • 222nm

Emission angle

  • 40°

*Tablet is not included. Android OS only. Recommended tablets for operation: Samsung Galaxy Tab A 8" or 10.1"; VANKYO MatrixPad S8, S10, or S30